Long‐term results of low‐intensity chemotherapy with clofarabine or cladribine combined with low‐dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia-Reference-Cited by-同舟云学术

Long‐term results of low‐intensity chemotherapy with clofarabine or cladribine combined with low‐dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia

Published:2021-05-26 Issue:8 Volume:96 Page:914-924
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Kadia Tapan M.¹^ORCID,Ravandi Farhad¹,Borthakur Gautam¹^ORCID,Konopleva Marina¹^ORCID,DiNardo Courtney D.¹^ORCID,Daver Naval¹^ORCID,Pemmaraju Naveen¹^ORCID,Kanagal‐Shamanna Rashmi²^ORCID,Wang Xuemei³,Huang Xuelin³,Pierce Sherry¹,Rausch Caitlin⁴^ORCID,Burger Jan¹,Ferrajoli Alessandra¹,Jain Nitin¹,Popat Uday⁵,Estrov Zeev¹,Verstovsek Srdan¹,Jabbour Elias¹^ORCID,Garcia‐Manero Guillermo¹^ORCID,Kantarjian Hagop¹

Affiliation:

1. Department of Leukemia University of Texas MD Anderson Cancer Center Houston Texas USA

2. Department of Hematopathology University of Texas MD Anderson Cancer Center Houston Texas USA

3. Department of Biostatistics University of Texas MD Anderson Cancer Center Houston Texas USA

4. Department of Pharmacy University of Texas MD Anderson Cancer Center Houston Texas USA

5. Department of Stem Cell Transplant University of Texas MD Anderson Cancer Center Houston Texas USA

Funder

National Cancer Institute

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26206

Reference48 articles.

1. De novo acute myeloid leukemia: A population‐based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017

2. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

3. Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy

4. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry

5. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome:

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Decitabine as epigenetic priming with CLAG induce improved outcome of relapsed or refractory acute myeloid leukemia in children;Clinical Epigenetics;2024-05-09

2. Efficacy and safety of venetoclax-based combination therapy for previously untreated acute myeloid leukemia: a meta-analysis;Hematology;2024-05-04

3. Low‐dose cytarabine and hypomethylating agents for Down syndrome with acute myeloid leukemia;Pediatric Blood & Cancer;2024-03-24

4. Unmet Horizons: Assessing the Challenges in the Treatment of TP53-Mutated Acute Myeloid Leukemia;Journal of Clinical Medicine;2024-02-14

5. Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in relapsed/refractory acute myeloid leukemia: results of a pilot study;Blood Cancer Journal;2024-01-18